Key result
Platelet-reactive antibodies occur in ~31% of stroke patients and link to better neurological recovery.
Why the study?
Platelets share similarities with neurons, but whether anti-platelet antibodies develop after ischaemic stroke and correlate with clinical outcomes remained unknown.
Population
48 ischaemic stroke patients and 50 controls
Comparison
Ischaemic stroke patients vs controls, and antibody-positive vs antibody-negative stroke patients
Design
Case-control study
Follow-up
Day 7 ± 2
Authors
Loading...
May support an endogenous antithrombotic response after stroke; leaves open prognostic or therapeutic utility pending prospective studies.
Case-Control (n=98)
No
Absolute Event Rate: 31% vs 4%
p-value: p=<0.001
Platelet-reactive antibodies are detectable early after ischaemic stroke and correlate with better short-term neurological recovery and reduced platelet aggregation, suggesting a novel endogenous antithrombotic mechanism.
Park et al. (2020) conducted a case-control in Ischaemic stroke (n=98). Ischaemic stroke vs. Healthy controls was evaluated on Presence of platelet-reactive antibodies (p=<0.001). Platelet-reactive antibodies were detected in 31% of patients after ischaemic stroke compared to 4% of healthy controls, and their presence correlated with better short-term neurological recovery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: